DRI Healthcare Trust T.DHT.UN

Back in Business

[retiredcf]

Following Thursday’s announcement of a US$57-million deal with Editas Medicine Inc. for a share of its annual license fees for the Cas9 gene-editing technology, CIBC’s Scott Fletcher raised his DRI Healthcare Trust (DHT.UN-T) target to $18.50 from $17.50 with an “outperformer” rating, , while Raymond James’ Michael Freeman increased his target to $23 from $20 with an “outperform” rating. The average is $18.68.

“We like deal’s elegant structure, its engagement with a highly innovative counterparty (potential for repeat business), and what it says about DRI’s dealmaking engine: it’s fully intact, and it’s revving high,” said Mr. Freeman.